These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 25588859)

  • 1. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
    Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
    Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
    Casaluce F; Sgambato A; Maione P; Rossi A; Ferrara C; Napolitano A; Palazzolo G; Ciardiello F; Gridelli C
    Target Oncol; 2013 Mar; 8(1):55-67. PubMed ID: 23325296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
    Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
    Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
    Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.
    de Figueiredo-Pontes LL; Wong DW; Tin VP; Chung LP; Yasuda H; Yamaguchi N; Nakayama S; Jänne PA; Wong MP; Kobayashi SS; Costa DB
    J Thorac Oncol; 2014 Feb; 9(2):248-53. PubMed ID: 24419423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
    Gainor JF; Varghese AM; Ou SH; Kabraji S; Awad MM; Katayama R; Pawlak A; Mino-Kenudson M; Yeap BY; Riely GJ; Iafrate AJ; Arcila ME; Ladanyi M; Engelman JA; Dias-Santagata D; Shaw AT
    Clin Cancer Res; 2013 Aug; 19(15):4273-81. PubMed ID: 23729361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
    Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
    Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.
    Lucena-Araujo AR; Moran JP; VanderLaan PA; Dias-Santagata D; Folch E; Majid A; Kent MS; Gangadharan SP; Rangachari D; Huberman MS; Kobayashi SS; Costa DB
    Lung Cancer; 2016 Sep; 99():17-22. PubMed ID: 27565908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
    Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.